Holen Sie sich die Stockscreener-App
0.812
4.47%
-0.038
Handel nachbörslich:
.82
0.008
+0.99%
Naya Biosciences Aktie (NAYA) Neueste Nachrichten
NAYA (NAYA Biosciences) Profitability Rank : 2 (As of Jun. 2024) - GuruFocus.com
NAYA Biosciences to Present Translational Insights to - GlobeNewswire
NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewswire
INVO Bioscience, Inc. announced that it has received $0.275 million in funding - Marketscreener.com
INVO Bioscience Closes Wisconsin Fertility Institute Acquisition - Marketscreener.com
INVO Bioscience Closes Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel Invocell System for Use in the Treatment of Infertility - Marketscreener.com
INVO Bioscience, Inc. Announces Appointment of Pressly Ahammed as Director of International Business Development - Marketscreener.com
INVOcell Appoints Yve Lyppens as Director Business Development Asia Pacific - Marketscreener.com
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
INVO Bioscience, Inc. Announces Grand Opening of "Positib Fertility, an INVO Center" in Monterrey, Mexico on November 1, 2021 - Marketscreener.com
INVO Bioscience Announces the Appointment of Steve Shum as Chief Executive Officer - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a - GlobeNewswire
NAYA (NAYA Biosciences) Enterprise Value : $15.50 Mil (As of Oct. 25, 2024) - GuruFocus.com
Top Premarket Gainers - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma - The Manila Times
The court declared bankruptcy of MPG AgroProduction OÜ - The Manila Times
INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 - Marketscreener.com
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC - Marketscreener.com
INVO Bioscience changes name, trading symbol after merger - Business Observer
INVO Bioscience confirms name change, new trading symbol following NAYA merger - TipRanks
INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences - The Manila Times
CERo Therapeutics, Inc. Provides Corporate Update - The Manila Times
INVO Bioscience (NASDAQ: INVO) Stock Sees Bullish Momentum on Merger News - DRP Journal
INVO Bioscience Completes Merger with NAYA Biosciences - TipRanks
Sarasota fertility company completes merger with bioscience firm - Business Observer
INVO Bioscience merges with NAYA, eyes oncology market - Investing.com
INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA) - The Manila Times
Sify Technologies announces the appointment of Ms. Padmaja Chunduru as Director on the Board - The Manila Times
INVO Bioscience, NAYA Biosciences close merger - TipRanks
INVO Bioscience secures $265,000 through Merchant Cash Advance - Investing.com India
INVO Bioscience faces Nasdaq delisting over share price - Investing.com
INVO Bioscience extends merger agreement with NAYA - Investing.com
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Sudden doctor departure at Middleton fertility clinic leaves patients unsettled - Madison.com
Naya Biosciences - The Pharma Letter
'We wasted a year': Abrupt shakeup at Wisconsin fertility clinic leaves families scrambling for answers - Milwaukee Journal Sentinel
INVO Bioscience receives Nasdaq compliance extension - Investing.com
Trading the Gap to Win in the Pre-Market - DataDrivenInvestor
Why Is Invo Bioscience (INVO) Stock Up 85% Today? - InvestorPlace
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
INVO Bioscience Seeks Funds After NAYA Misses Deadline - TipRanks
NAYA buys gene therapy company Florida Biotech for $20m - Pharmaceutical Technology
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON) - GlobeNewswire
CGT Landscape: Recent Approvals, Deals And 2024 Catalysts - In Vivo
INVO Bioscience Files S-4 Registration and Preliminary - GlobeNewswire
Ten NK cell therapy companies to look out for this year - Labiotech.eu
Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered - Labiotech.eu
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal - PR Newswire
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies - PR Newswire
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement - PR Newswire
INVO Reports Record Third Quarter 2023 Financial Results - PR Newswire
NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger - PR Newswire
Free Registration Is Now Open For Tribe Public's CEO and Q&A Presentation Webinar Event "Accelerating Biotech Value Creation" Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023 - PR Newswire
INVO Bioscience And NAYA Biosciences Merging To Establish Expanded Publicly Traded Life Science Company - Pulse 2.0
INVO BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of INVO Bioscience, Inc.INVO - Marketscreener.com
Why Is INVO Bioscience (INVO) Stock Up 325% Today? - InvestorPlace
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 - Marketscreener.com
INVO Closes Acquisition of Wisconsin Fertility Institute - PR Newswire
INVO Bioscience Announces Pricing of $4.5 Million Public Offering - PR Newswire
INVO Receives 510(k) FDA Clearance for Expanded Use of the INVOcell Device - PR Newswire
Transcript : INVO Bioscience, Inc., Q4 2022 Earnings Call, Apr 17, 2023 - Marketscreener.com
NAYA enacts four-day workweek following modular cleanroom production expansion - Cleanroom Technology
INVO Bioscience, Inc. announces Launch of INVOcell in Malaysia by Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz - Marketscreener.com
INVO Bioscience, Inc. Signs Distribution Agreement with Onesky Holding Limited for Mainland China - Marketscreener.com
INVO Bioscience Expands U.S. Commercialization Efforts - PR Newswire
INVO Bioscience Obtains Regulatory Approval to Commercialize INVOcell In Thailand - Marketscreener.com
INVO Bioscience Regains Full U.S. Commercialization Rights - PR Newswire
INVO Bioscience Announces Official Opening of "Bloom Fertility, an INVO Center" in Atlanta - PR Newswire
INVO Bioscience, Inc. Appoints Rebecca Messina as Director - Marketscreener.com
INVO Bioscience Advances Commercialization into the European Fertility Market with Initial Orders of INVOcell in Spain - Marketscreener.com
1.38%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):